- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mirada recruits German hospital
University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to
University Hospital Essen has signed an agreement with Mirada Solutions, a unit of CTI Molecular Imaging, to serve as the company's first European clinical reference site. German physicians will use Mirada software in a combined PET/CT environment to address software fusion requirements as a complement to conventional hardware-based techniques. The hospital has been working with PET/CT imaging since October 2001. The collaboration is the first step toward establishing R&D partnerships among leading European institutions, CTI, and its subsidiaries, including Mirada Solutions and PETNET Pharmaceuticals. Mirada joined CTI Aug. 18, when CTI purchased all of Mirada's capital stock.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
